The biotechnology company strengthens its leadership with an experienced biopharma executive as it prepares to advance relcobatinib for previously treated chronic myeloid leukemia.
Enliven Therapeutics, Inc. (Nasdaq: ELVN), a clinical-stage biopharmaceutical company developing small-molecule therapeutics, has announced the appointment of Kristine Ball to its Board of Directors, effective immediately.
Ball brings more than 20 years of executive experience across clinical-stage and commercial-stage biotechnology companies, with expertise in corporate strategy, financial management, commercialization planning, and corporate governance.
Her appointment comes as Enliven prepares to initiate the pivotal Phase 3 trial of relcobatinib (ELVN-001) in previously treated chronic myeloid leukemia (CML) before the end of 2026.
Key Highlights
-
Board appointment: Kristine Ball joins Enliven Therapeutics' Board of Directors, effective immediately.
-
Industry experience: More than 20 years of executive leadership in the biotechnology sector.
-
Leadership background: Previously served as CEO of Antiva Biosciences and Soteria Biotherapeutics, along with senior leadership roles at Menlo Therapeutics and Relypsa.
-
Clinical milestone: Enliven plans to initiate the pivotal Phase 3 trial of relcobatinib before year-end 2026.
-
Regulatory progress: The company recently announced FDA alignment on the final design of the ENABLE-2 study.
Kristine Ball's Leadership Experience
Ball brings extensive experience in biotechnology leadership, financial strategy, corporate development, and commercialization readiness.
Her previous executive positions include:
-
Antiva Biosciences: Chief Executive Officer.
-
Soteria Biotherapeutics: Chief Executive Officer.
-
Menlo Therapeutics: Senior Vice President of Corporate Strategy and Chief Financial Officer.
-
Relypsa: Senior Vice President and Chief Financial Officer, where she helped guide the company's transition from clinical development to commercial operations.
Ball currently serves on the Board of Directors of Oruka Therapeutics, where she chairs the Audit Committee. She has also previously served on the boards of Atreca and Forty Seven.
She holds a Bachelor of Science degree from Babson College.
Leadership Perspectives
Enliven CEO Rick Fair welcomed Ball to the Board, highlighting her experience in guiding biotechnology companies through the transition from clinical development to commercial operations.
He noted that her expertise will be valuable as the company prepares for the pivotal Phase 3 trial of relcobatinib and develops its commercialization strategy.
Ball said her personal connection to chronic myeloid leukemia through a family member strengthened her interest in Enliven's mission. She expressed enthusiasm for supporting the company's leadership team as it advances relcobatinib and prepares for its next stage of growth.
Relcobatinib: Advancing Treatment for Chronic Myeloid Leukemia
Relcobatinib (ELVN-001) is an investigational small-molecule therapy being developed for patients with previously treated chronic myeloid leukemia.
CML is a type of blood cancer characterized by the abnormal growth of myeloid cells in the bone marrow. Treatment advances have improved outcomes for many patients, but some continue to face challenges with existing therapies, creating a need for additional treatment options.
Enliven recently announced that it had aligned with the U.S. Food and Drug Administration (FDA) on the final design of its ENABLE-2 pivotal Phase 3 trial. The company plans to initiate the study before the end of 2026.
The upcoming trial represents a key milestone in relcobatinib's clinical development. The candidate remains investigational, and its safety and efficacy must be established through clinical studies.
About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for unmet medical needs.
The company uses a precision medicine approach that combines insights into clinically validated biological targets with differentiated chemistry to develop potential first-in-class or best-in-class treatments. Its mission is to help patients not only live longer but also experience a better quality of life.
Enliven is headquartered in Burlingame, California.
For more information, visit https://www.enliventherapeutics.com.
Outlook
Ball's appointment adds experienced executive and financial leadership to Enliven as it approaches a pivotal stage in its development program.
With the planned initiation of the ENABLE-2 Phase 3 trial before year-end 2026, the company is preparing to advance relcobatinib for previously treated CML while strengthening its readiness for potential future commercialization.
